Zimberelimab (AB122)
Multiple Solid Tumors
Phase 3Active
Key Facts
About Arcus Biosciences
Founded in 2015, Arcus Biosciences is a clinical-stage biopharma with a mission to develop best-in-class cancer therapies through its proprietary 'Combining to Cure®' philosophy. The company has built a fully integrated platform, advancing a deep pipeline targeting key immuno-oncology pathways like adenosine signaling and TIGIT. With strategic partnerships, including a major collaboration with Gilead Sciences, and multiple programs in late-stage development, Arcus is positioned as a significant player in the next wave of oncology combination treatments.
View full company profileTherapeutic Areas
Other Multiple Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| CLD-401 | Calidi Biotherapeutics | IND-Enabling |
| Early Cancer Detection Platform | Astrin Biosciences | Pre-clinical |
| ABC (²¹²Pb-undisclosed) | ARTBIO | Discovery |
| SonoLeukin™ | Vesselon | Pre-clinical |
| ELEPHAS-04 (Mayo Clinic) | Elephas Biosciences | Observational |
| ORIC-101 | ORIC Pharmaceuticals | Phase 1b |
| MGC026 | MacroGenics | Phase 1 |
| MGC028 | MacroGenics | Phase 1 |
| MGC030 | MacroGenics | Preclinical |
| EB103 + Oncolytic Virus | Estrella Immunopharma | Discovery/Preclinical |